scPharmaceuticals (SCPH)
(Delayed Data from NSDQ)
$4.58 USD
+0.09 (2.00%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $4.59 +0.01 (0.22%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
scPharmaceuticals, Inc. [SCPH]
Reports for Purchase
Showing records 1 - 20 ( 38 total )
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Signs Around, Despite Impact from Cyberattack; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Good Quarter for Furoscix; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SCPH 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Launch Metrics Continue to Look Good; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Furoscixs Launch is Off to a Good Start; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
An Easy Label Expansion Should Open Up the Opportunity Further; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Furoscix Delivers Encouraging Early-Launch Indicators; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ready to Hit the Ground Running with Furoscix; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Launch Game Plan in Place; Reiterate Buy; Raise PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The FDA Says "Yes": Furoscix Receives FDA Approval, Launched Expected in January 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HFSA Presentations Highlight Furoscix Value Proposition Ahead of Potential Launch; Reiterate Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NDA Accepted with October PDUFA Pointing to 4Q Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NDA Gets Refiled With Time to Spare; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Rx for Portfolios, Part 2: Companies With Significant Upcoming Regulatory Decisions
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: scPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Furoscix On Track for Potential 4Q22 Commercialization Despite Modest Delay in Resubmission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D